Priced Out of Prevention: How America's Insurance Patchwork Is Keeping TB Screening Out of Reach

When Maria Delgado, a home health aide in Houston, Texas, developed a persistent cough in the winter of 2022, she did not immediately seek care. She had insurance—a bare-bones plan purchased through the federal marketplace—but she had learned through experience that "having coverage" and "being able to afford care" were rarely the same thing. When she finally visited a clinic, her physician recommended tuberculosis testing. What followed was a months-long struggle with prior authorization requests, denied claims, and rescheduled appointments that delayed her diagnosis by nearly four months.

Maria's story is not an anomaly. Across the United States, insurance coverage disparities are functioning as a silent barrier to tuberculosis screening, transforming a manageable public health tool into a bureaucratic obstacle course for millions of Americans.

A System Built on Gaps

The United States does not have a uniform standard for tuberculosis screening coverage. Instead, what exists is a fragmented mosaic of policies that vary by insurer, by state, and by the type of plan a patient holds. Under the Affordable Care Act, preventive services with an "A" or "B" rating from the U.S. Preventive Services Task Force are required to be covered without cost-sharing by most private insurers. Tuberculosis screening does not currently hold such a rating for the general population, which means that for millions of privately insured Americans, TB testing may be subject to deductibles, copayments, or outright exclusion.

Medicaid coverage—the program that serves many of the communities at highest TB risk—varies dramatically from state to state. In some states, both tuberculin skin tests and interferon-gamma release assays (IGRAs), the two primary diagnostic tools for latent TB infection, are covered comprehensively. In others, coverage is limited to one test type, requires prior authorization, or is restricted to specific clinical circumstances. For patients who fall into these gaps, the practical result is often no screening at all.

"We have communities where TB rates are significantly elevated, and we have people in those communities who cannot access a forty-dollar blood test because of how their insurance is structured," said one county public health official in Southern California, who requested anonymity to speak candidly about systemic failures. "That is not a medical problem. That is a policy problem."

The Prior Authorization Trap

Even when coverage technically exists, prior authorization requirements can render it functionally useless. Prior authorization—the process by which insurers require advance approval before covering certain services—has come under increasing scrutiny across multiple areas of medicine. In the context of tuberculosis, where timely diagnosis is critical to preventing transmission, these delays carry particular weight.

Public health clinicians interviewed for this article described cases in which prior authorization requests for IGRA testing took anywhere from one week to several months to resolve. In some instances, approvals were denied on the grounds that the clinical justification was insufficient, even when the patient had documented exposure to an active TB case. Appeals processes, while technically available, require time, documentation, and health literacy that many patients—particularly those who are uninsured, underinsured, or navigating language barriers—do not have.

Dr. Priya Nair, an infectious disease physician practicing in Chicago, described the situation bluntly. "I have had patients sit in limbo while we wait for an insurer to decide whether they deserve a TB test. Meanwhile, if that person has active disease, they are potentially exposing others. The authorization process was not designed with infectious disease transmission in mind."

State-by-State: A Map of Unequal Access

An analysis of state Medicaid coverage policies reveals striking disparities in how tuberculosis screening is treated across the country. States with higher TB burden, including California, Texas, New York, and Florida, generally offer broader coverage—but even within these states, coverage gaps persist for specific populations, including undocumented immigrants, people in short-term coverage transitions, and those enrolled in limited-benefit plans.

In contrast, several states with lower absolute TB case counts but significant at-risk populations have more restrictive coverage frameworks, creating situations where people who have recently immigrated from high-burden countries, individuals experiencing homelessness, or those recently released from correctional facilities may find themselves unable to access recommended screening.

The consequences extend beyond individual health outcomes. When latent TB infections go undetected and untreated, they become a reservoir for future active disease. Public health researchers estimate that without sustained investment in latent TB identification and treatment, the country's already-strained TB elimination efforts will face compounding setbacks over the next decade.

The Human Cost of Coverage Denial

Behind every data point is a patient whose trajectory was altered by a coverage decision. James Whitfield, a construction worker in Atlanta, was referred for TB screening after a coworker was diagnosed with active disease. His employer-sponsored insurance plan denied coverage for the IGRA test his physician ordered, classifying it as "not medically necessary" based on a boilerplate review. The skin test alternative was available, but James had a documented history of a false-positive reaction to the tuberculin skin test due to a prior BCG vaccination received abroad. His physician submitted an appeal. It was ultimately approved—six weeks later.

"Six weeks is a long time when you are worried about whether you have tuberculosis," James said. "And I kept thinking about the people I work with every day."

Patient advocates emphasize that these experiences are not isolated failures of individual insurers. They are the predictable outcome of a coverage architecture that was never comprehensively designed around infectious disease prevention.

What Reform Could Look Like

Public health officials and policy advocates have outlined several approaches that could meaningfully expand access to TB screening. Chief among them is a formal USPSTF recommendation that would trigger mandatory no-cost coverage for high-risk populations under private insurance plans. Advocates have urged the task force to accelerate its review of the evidence base for targeted TB screening, arguing that the existing data on cost-effectiveness and health impact is sufficient to support action.

At the state level, Medicaid agencies could standardize coverage for both IGRA and tuberculin skin testing without prior authorization requirements, particularly for individuals in recognized high-risk categories. Several states have already moved in this direction, and their experiences offer a model for broader adoption.

Federally qualified health centers and public health clinics provide a critical safety net for uninsured and underinsured patients, but their capacity is limited and unevenly distributed. Sustained federal investment in these settings—combined with clearer reimbursement pathways—would help ensure that insurance status does not determine whether a person receives a potentially life-saving test.

Screening as a Public Health Imperative

Tuberculosis is not a disease of the past. It is an ongoing public health challenge that disproportionately affects communities already navigating significant structural disadvantages. When insurance systems erect barriers to screening, they do not merely inconvenience individual patients—they undermine the collective effort to contain a communicable disease.

The tools to diagnose tuberculosis exist. The clinical knowledge to interpret results and initiate treatment exists. What remains inadequate is the policy infrastructure to ensure that those tools reach everyone who needs them, regardless of the plan they carry in their wallet or the state in which they happen to live.

Until that infrastructure is strengthened, millions of Americans will remain unscreened—not because medicine failed them, but because the system was not built to reach them.